• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Technology

Biotech, Chips Stand Their Ground

You can't help but feel better about both groups.
By JIM CRAMER Mar 27, 2015 | 12:00 PM EDT
Stocks quotes in this article: PCYC, ABBV, JNJ, PFE, AMGN, REGN, BMRN, SWKS, AVGO, QRVO, NXPI, INTC, MU, QCOM, TSM

The four horsemen of the semiconductors and the four horsemen of biotech are standing their ground, and it could bode well for a stand in two leadership groups that have been hammered, and were the proximate causes of this week's decline.

Exactly one week ago today proved to be the peak in biotech, as overenthusiasm for the group crested and a rapid selloff began. What caused that top? We had seen an unprecedented wave of mergers and acquisitions, culminating with a monster bid for Pharmacyclics (PCYC) by a conservative company, AbbVie (ABBV), which left two other big drug companies, rumored to be Johnson & Johnson (JNJ) and Pfizer (PFE), at the altar, ready to do a big deal. We had gotten some amazing results out of a new class of anti-bad cholesterol drugs from Amgen (AMGN) and Regeneron (REGN). Plus, Biogen (BIIB) released positive results of its study of a formulation that could roll back Alzheimer's disease, a potential $15 billion blockbuster drug.

That got the group overheated and lots of smaller, non-profitable techs were taken up in the wake of this terrific news flow. Fortunately, the overheated companies didn't issue a lot of equity, and while a bubble of sorts has certainly become evident among a lot of small companies with Phase 1 and 2 formulations that may never pan out, the ability of the four horsemen to rally today after that smack-down is a very positive sign. It doesn't hurt either that BioMarin (BMRN) is running on takeover talk. Nothing like a little M&A action -- real or not -- to get the shorts' juices flowing.

Is there a bottom in the group? How about a needed shakeout running its course?

We had a parallel crushing of the best of the semiconductors, the ones with the most proprietary content linked to cellphones and connectivity, notably Skyworks Solutions (SWKS), Avago (AVGO), Qorvo (QRVO) and NXP Semiconductors (NXPI). There's been carnage for months in the semi space, including real bloodletting in Intel (INTC), Micron (MU) and Qualcomm (QCOM). The problems here? Intel and Micron, which reports next week, are seen as too linked to personal computers, which are in secular decline. They don't have the leverage to connectivity that the new big four have. Qualcomm's core cellphone business seems to be slowing along with some real complications in its business in China.

We thought the pain was cordoned off to those three. But earlier this week we got negative comments from Taiwan Semiconductor (TSM) -- a mostly ignored behemoth -- that there's inventory in the cellphone channel. Inventory is the bane of the existence of these parts companies and those comments sent all the traders scurrying away from all stocks in the group, not just those geared toward personal computers.

Into that breach steps David Aldrich, CEO of Skyworks, arguably the best of the lot, who gave you terrific reassurance on Mad Money last night that things are very much on course and as red-hot as ever. The new cellphones are so complicated and have so many proprietary parts that the gross margins for these companies are actually going higher -- quite a difference from the old days. Skyworks has about $5 of content in a new Apple (AAPL) phone, which means that their business has tremendous momentum. Plus, Aldrich made it clear that the trend is long term. He likes to say he is "following the money," plying his chips into all sorts of connected applications in cars, homes, medicine and defense, among many other sectors.

Again, I came away thinking that these stocks, too, can bottom and the problem children in the group each have their own issues that don't bleed into the territory of the four tech horsemen.

The leadership in semis and the leadership in biotechs are asserting themselves in ways that say weak hands are exiting. That's precisely what must happen if these two groups are to power beyond the highs reached within the past week. After today, you can't help but feel better about both groups, which looked like they were on the ropes just a few short days ago.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline on this article.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long AAPL.

TAGS: Investing | U.S. Equity | Technology

More from Technology

How to Move on MongoDB

Bruce Kamich
May 20, 2022 2:19 PM EDT

Let's take a technical follow-up look at MDB -- and give a word of caution on this software name.

I'm Cautious on Marvell Technology Ahead of Earnings

Bruce Kamich
May 20, 2022 11:52 AM EDT

Let's review the charts and indicators.

If You're Looking for a Hero in This Market, Don't Look to Apple, ARKK

Ed Ponsi
May 20, 2022 10:30 AM EDT

Folks are asking if it's finally time to buy the ARK Innovation exchange-traded fund or Apple. Let's check the charts.

Don't Be in a Rush to Invest in Cisco

Stephen Guilfoyle
May 19, 2022 11:00 AM EDT

Someone already long this stock, who has taken a hit, doesn't need to liquidate unless...

Alteryx Has Yet to Bottom Based on Its Charts

Bruce Kamich
May 19, 2022 9:04 AM EDT

The technical signs indicate that the stock of the data analytics company still needs to build a base.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An interesting chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login